{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:33:53Z","timestamp":1770723233077,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:57:50Z","timestamp":1763693870000},"page":"e213-e222.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1491-5358","authenticated-orcid":false,"given":"Borja","family":"Puertas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-4882","authenticated-orcid":false,"given":"Elena","family":"Alejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 J.","family":"P\u00e9rez-Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fe","family":"Serra-Toral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"D\u00e1vila-Valls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5480-5272","authenticated-orcid":false,"given":"Ar\u00e1nzazu","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-5616","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Alonso-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Aguilar-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-060X","authenticated-orcid":false,"given":"Alfonso","family":"Garc\u00eda-Coca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9690-3807","authenticated-orcid":false,"given":"Alberto","family":"Cantalapiedra-Diez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-6105","authenticated-orcid":false,"given":"Abelardo","family":"B\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Rey-B\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-4387","authenticated-orcid":false,"given":"Juan","family":"Flores-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-3673","authenticated-orcid":false,"given":"M Bel\u00e9n","family":"Vidriales-Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.11.007_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.clml.2025.11.007_bib0002","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2025.11.007_bib0003","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"},{"issue":"10192","key":"10.1016\/j.clml.2025.11.007_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.11.007_bib0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.11.007_bib0006","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.bbmt.2020.04.016","article-title":"Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? A review from the chronic malignancies working party of the EBMT","volume":"26","author":"Garderet","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"S2","key":"10.1016\/j.clml.2025.11.007_bib0007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.HS9.0000936220.68605.8b","article-title":"P23 EMAGINE\/CARTITUDE-6: a randomized phase 3 study of DVRd followed by Ciltacabtagene Autoleucel versus DVRd followed by autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"7","author":"Broijl","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.11.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease\u2013guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.11.007_bib0009","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance\u2013like phenotype in patients with monoclonal gammopathies","volume":"16","author":"Burgos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.11.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"The Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.11.007_bib0011","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2025.11.007_bib0012","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.clml.2025.11.007_bib0013","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.11.007_bib0014","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2025.11.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"The Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.11.007_bib0016","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.11.007_bib0017","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/ajh.27414","article-title":"Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma","volume":"99","author":"Kostopoulos","year":"2024","journal-title":"American J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.11.007_bib0018","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2023-180351","article-title":"The specific transcriptional signature and clonal selection of MGUS-like profile predict an exceptionally favorable prognosis in patients with newly-diagnosed multiple myeloma","volume":"142","author":"Yan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.11.007_bib0019","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.2024025421","article-title":"MRD accelerating myeloma drug development","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.11.007_bib0020","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S2152-2650(24)01860-3","article-title":"OA-19 marrow immune features are most informative of early MRD negative treatment response in newly diagnosed TE patients: insights from the UKMRA phase 3 RADAR study","volume":"24","author":"Mehta","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.clml.2025.11.007_bib0021","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.11.007_bib0022","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2024-200871","volume":"144","author":"Zweegman","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2025.11.007_bib0023","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.11.007_bib0024","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.11.007_bib0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood-2023-179866","volume":"142","author":"Mateos","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:17:11Z","timestamp":1770650231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042934"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}